Introduction
Renal transplantation is the optimum treatment for many patients with end-stage renal failure (1) . A major challenge of renal transplantation is chronic allograft damage (CAD) characterized by interstitial fibrosis and tubular atrophy. The pathophysiology is poorly understood and multiple cell mediators and mechanisms are involved (2) . B cells have been identified in biopsies of renal transplants with stable function (3) , in the context of acute rejection (4, 5) , and chronic damage (6) . However, other studies have not correlated the presence of B cells to be detrimental (7) , and B cells have been associated with the development of ectopic lymphoid tissue, also termed tertiary lymphoid tissue (TLT), within the human renal allograft (8) . Although TLT in humans has been found in multiple chronic inflammatory disease states (9) , the role of intra-allograft B cells and their significance have not been well explored (10) .
The presence of B cells infiltrating inflammatory tissue in other models of disease has been associated with worse injury. Early depletion of B cells in myocardial infarction reduced the number of B cells recruited to the tissue and this was associated with significant improvement in post infarction cardiac function, furthermore, recruitment of macrophages into the tissue and subsequent fibrosis were reduced (11) . In a similar manner, liver fibrosis was attenuated in mice deficient in intrahepatic B cells (12) , and CD19 deficient mice developed less Beomycin-induced pulmonary fibrosis (13) .
However, the nonspecific depletion of B cells has been met with caution as the presence of regulatory B cells has been associated with protection from disease in some models (14, 15) . Indeed, a clinical study of B cell depletion as induction to renal transplantation was associated with a significant increase in acute rejection (16) . There has been increasing interest in the functions of B cells beyond their role in antibody production, including cytokine-mediated effects in human disease (17, 18) . In this report, we have shown that intra-allograft B cells are key mediators of CAD and that B cells possibly contribute to CAD by intra-allograft secretion of cytokines and chemokines.
Materials and Methods

Mice and renal transplantation
Experiments performed under a UK Home Office Project License, granted under the Animal (Scientific Procedures) Act 1986 and approved by the University of Edinburgh ethical review committee. Eight-week old male C57BL/6 and BALB/c mice were obtained from Charles River, and C57BL/ 6 BM12 colonies maintained in specific pathogen-free conditions in the Biological Research Resources Center Edinburgh. Survival was greater than 80% for study groups. Anesthesia was with intraperitoneal ketamine (75 mg/kg) and medetomidine (1 mg/kg), the donor kidney was perfused with cooled University of Wisconsin solution (Belzer Bridge to Life), the surgical technique was as previously reported (19) . Renal transplantation was performed with a mean warm ischemic time of 30 min. The donor ureter was anastomosed to recipient bladder. Anesthesia was reversed with subcutaneous injection of atipamezole (1 mg/kg) and buprenorphine (0.05 mg/kg) for analgesia, with 1 mL of 0.9% NaCl injected subcutaneously. The mouse was recovered and monitored in a warming cabinet at 288C. A single intact native kidney was left in situ and the model was not transplantdependent. To model CAD, heterotopic kidney transplantation was performed from a C57BL/6 BM12 (H-2B BM12 ) donor into a C57BL/6 (H-2B) recipient as previously described (19, 20) . To model acute rejection, a C57BL/ 6 BM12 donor kidney was transplanted into a BALB/c (H-2d) recipient. For the isograft group, C57BL/6 kidneys were transplanted into litter mates.
B cell depletion
B cell depletion was performed by a single tail vein intravenous injection of 300 mg anti-mouse CD20 mAb (18B12, IgGm2a; Biogen Idec, San Diego, CA) in 200 mL 0.9% NaCl, as described previously (21) . Control placebo treated mice received anti-human anti-CD20 mAb (rituximab; Biogen Idec, Cambridge, MA).
Histology
Immunohistochemistry, immunofluorescence methods, and microscopy equipment are given in supplementary materials. Tubules within the cortex (200Â magnification, 10 fields) were counted using ImageJ software (Cell counter plugin; ImageJ 1.22o; National Institutes of Health, Bethesda, MD). B220 þ B cell, CD3 þ T cells, F4/80 þ macrophages, picrosirius red, collagen III, SM22, PDGFR-b, and a-SMA were expressed as average % area per high powered field (200Â magnification, 10 fields) using a verified methodology of positive staining using Color Range tool on Photoshop CS6 Extended (Version 13.0.6; Adobe Systems Europe) (22) . Absolute numbers of LYVE1 þ lymphatic vessels and PNAd þ high endothelial venules through the whole tissue section were expressed per mm 2 of the total tissue area calculated using ImageJ software. Pathological grading of T cell inflammation based on modified average T-score for each kidney (200Â magnification, 10 fields, each given t-score of greatest degree per field) (23) . T-score was calculated by T0 ¼ no mononuclear cells in tubules, T1 ¼ foci with 1-4 cells/tubular cross-section (or 10 tubular cells), T2 ¼ foci with 5-10 cells/tubular crosssection, T3 ¼ foci with >10 cells/tubular cross-section, or the presence of at least two areas of tubular basement membrane destruction.
Kidney digestion
Single cell suspension from kidney digestion was prepared by mechanically fragmenting tissue using a No. 23 scalpel (Swann-Morton, UK) into IMDM (GIBCO Life Technologies, Paisley, UK), 5% fetal calf serum (Biosera, Europe, France), and 1% penicillin/streptomycin (PAA Laboratories GmbH, Austria). The homogenate was centrifuged (5 min, 300g) and re-suspended in 2 mL Hanks buffer (PAA Laboratories GmbH) containing 1.6 mg/mL collagenase B (Roche Diagnostics GmbH, Mannheim, Germany) and 100 g/ mL DNAse I (Roche Diagnostics GmbH, Mannheim, Germany), and incubated at 378C for 30 min with occasional rotational mixing. The homogenate was passed through a 40 mm cell strainer (BD Biosciences, Oxford, UK) and cells were centrifuged (5 min, 300g) . Red blood cells were lysed by incubation on ice with red cell lysis buffer (Sigma-Aldrich, St. Louis, MO) for 10 min.
Flow cytometry
For splenocyte and allograft lymphocyte flow cytometry cell analysis 1 Â 10 6 cells were stained for 30 min at 48C with primary antibodies given in supplementary materials. Cells were washed and DAPI added immediately before analysis using BD FACSDIVA version 6.1.3 on a LSR Fortessa (BD Biosciences). Analysis was gated on collecting 10 000 live B cell events. Post acquisition data analysis was performed using FlowJo version 10.6 (TreeStar, Inc., Ashland, OR). For peripheral flow cytometric analysis, 12.5 mL of peripheral blood was obtained by tail vein bleeding and added to 3.8% sodium citrate; aforementioned primary antibodies in 1% PBS were added and stained for 30 min at 48C before FACS lysing solution (BD Biosciences, San Jose, CA) was added before data acquisition along with CountBright Beads (Invitrogen, Paisley, UK). See supplementary materials for cell sorting methods.
Circulating immunoglobulin titration
Blood was obtained by cardiac puncture with a 21G needle (Microvette 600, Germany) and serum was separated by centrifugation (10 000G, 5 min) and frozen at À208C till use. Determination of serum antibody concentrations was performed with a Luminex multiple analyte immunoglobulin profiling magnetic bead assay (Procartaplex, eBioscience, San Diego, CA), prior to incubation with the bead assay serum was diluted 1:10 000 with universal buffer supplied within the assay kit. Luminex data acquisition was performed on a Bio-plex 200 system (Bio-Rad, Hercules, CA) and analysis was performed using Bio-plex manager software (Version 6.0, Bio-Rad Labs, Inc.).
Anti-donor antibody determination
Allospecific antibodies in sera of transplant recipients were assessed using indirect flow cytometry. Serum was assayed for anti-donor antibodies by their ability to bind C57BL/6 BM12 splenocytes using flow cytometry. Splenocytes (0.5 Â 10 6 ) were incubated in 50 mL Dulbecco's PBS (PAA Laboratories GmbH) containing 1:20 recipient serum for 30 min at 48C followed by washes with PBS. Goat F(ab') 2 polyclonal anti-IgG-FCphycoerythrin (ABCAM, Cambridge, UK) was added and further incubated for 30 min. Fluorescence analysis was determined by flow cytometry using a LSR Fortessa (BD Biosciences, Oxford, UK) and median fluorescence intensity measured post-acquisition using FlowJo (Tree Star, Inc.). Conditions were performed in technical triplicates for samples derived from individual mice. In a similar manner, auto-antibodies in the sera of transplant recipients were assessed using permeabilized cells. Splenocyte permeabilization (Foxp3 Fixation/Permeabilization Set, eBioscience) was performed prior to incubation with diluted recipient serum.
B cell cytokine assay
Following FACS B cell isolation, 2.5 Â 10 5 B cells were incubated in a 96-well plate in 250 mL of IMDM (GIBCO, Life Technologies), 10% FCS (Biosera), and 1% penicillin and streptomycin (PAA Laboratories GmbH) for 72 h. In separate wells, B cells were stimulated with ionomycin 1 mg/mL and PMA 20 ng/mL or 2.5 Â 10 5 g-irradiated C57BL/6 BM12 splenocytes (Caesium-137, 30 Gy). Determination of the presence of multiple cytokines was performed with a Luminex multiple analyte cytokine profiling magnetic bead assay (eBioscience or Bio-Rad). Luminex data acquisition was performed on a Bioplex 200 system (Bio-Rad, Hercules, CA) and analysis was performed using Bio-plex manager software (Version 6.0, Bio-Rad Labs, Inc.).
Statistical analysis
Data expressed as mean (SEM, standard error of the mean) unless otherwise stated. ANOVA (within groups and between multiple groups) with post hoc Bonferonni test, unpaired student's t-test (for parametric datasets), and Mann-Whitney U tests (for nonparametric), were performed using Prism 5 for Mac OS X software (GraphPad Software, Inc., La Jolla, CA). A p-value of less than 0.05 was considered significant.
Results
Mature B cells are recruited to the renal allograft
In CAD, a progressive loss of tubules occurred over a 12week period, no difference in the number of healthy tubules between native kidneys and isograft kidneys was observed ( Figure 1A , CAD vs. Isograft ANOVA p < 0.0001). The loss of nephron mass was accompanied by interstitial fibrosis, identified by picrosirius red staining of fibrillar collagen within the renal parenchyma. Following isograft transplantation, minimal fibrosis developed with scarring being significantly greater in CAD kidneys ( Figure 1B , CAD vs. isograft ANOVA p < 0.0001). There was a progressive accumulation of B220 þ B cells within the allograft predominantly originating in a perivascular location, peaking at 12 weeks, whereas isograft kidneys were devoid of B cells ( Figure 1B , ANOVA p < 0.0001).
B cells form germinal centers and tertiary lymphoid tissue
Immunofluorescence confirmed B cells forming GL7 þ germinal centers and the presence of CD138 þ plasma cells in 12-week allograft kidneys ( Figure 1C ). The development of TLT was further supported by the presence of LYVE1 þ lymphatics and PNAd þ high endothelial venules ( Figure 1C ). Compartmentalization of intraallograft B cells into TLT was suggested by the presence of B cells that were either IgM high CD23 À , IgM lo CD23 þ , or IgM lo CD23 À (Figure 2A and B) suggesting some similarities with those found in spleen and found in a similar population distribution ( Figure 2C ). In addition, a greater percentage of intra-allograft B cells expressed CD86 (B7-2) than na€ ıve spleen B cells ( Figure 2C , ANOVA p < 0.0001), though there was no difference in CD80 expression between allograft B cells, na€ ıve, or allograft spleen B cells.
B cell depletion reduces interstitial fibrosis and tubular loss
To investigate whether the progression of CAD could be modified, B cell depletion at 4 weeks after transplantation was performed. A monoclonal anti-CD20 approach was used to replicate human studies (16) . This strategy effectively depleted peripheral blood CD45.2 þ B220 þ B cells compared to placebo anti-human anti-CD20 (rituximab) treatment ( Figure 3A) . Peripheral blood B cells remained significantly suppressed for up to 4 weeks ( Figure 3B, 8 The effect of B cell depletion in CAD model is predominantly independent of antibody Transplanting a C57BL/6 kidney into a BALB/c recipient is known to result in IgG donor-specific antibody and this was used as a positive control ( Figure 6A and B, p < 0.0001, ANOVA) (24) . In CAD mice, serum concentration of IgM and total IgG were elevated at 4 weeks following allograft transplantation compared to na€ ıve levels ( Figure 6A ). The elevated IgG isotype in CAD mice appeared to be of IgG1 and IgG3 subclass, IgG2a concentration was not elevated in C57BL6 recipients; however, IgG1, IgG2a, and IgG3 were elevated in BALB/c recipients ( Figure S2 ). No IgG reactivity was observed against fresh C57BL/6 BM12 splenocytes in serum from C57BL/6 recipients, compared to a significant increase in the median fluorescence intensity (MFI) cell surface IgG binding following incubation with serum from BALB/c recipients ( Figure 6B , p < 0.0001, ANOVA). To investigate auto-antibody generation, C57BL/6 BM12 splenocytes were permeabilized prior to incubation with serum. Although an increase in MFI of IgG was observed in CAD mice compared to na€ ıve C57BL serum, B cell depletion after transplantation had no effect on the presence of autoreactive IgG (data not shown). IgG was apparent in the allograft tissue ( Figure 6C) ; however, IgM did not appear to be present within the allograft other than that expressed on the surface of B cells. B cell depletion by anti-CD20 did not reduce the amount of IgG in the CAD kidney either at 8 or 12 weeks posttransplantation ( Figure 6C, 8 weeks p ¼ 0.4848 and 12 weeks p ¼ 0.2403, U test). Lastly, the complement split product C4d was not detected in rejecting allografts further suggesting that antibody-mediated rejection is not involved in this model of CAD. Glomerulopathy was not a feature, with normal glomeruli demonstrated in the presence of IFTA ( Figure 4D ). T cell accumulation is reduced by B cell depletion T cells were identified in perivascular regions as well as dispersed throughout the kidney parenchyma where they infiltrated glomeruli and tubules ( Figure 7A) . B cell depletion at 4 weeks after transplantation significantly reduced T cell density ( Figure 7B, 8 weeks p ¼ 0.0052 and 12 weeks p ¼ 0.0002, U test), and the t-score (reflecting the level of pathological T cell-mediated injurious tubulitis) at 8 weeks ( Figure 7B, 8 weeks p ¼ 0.045, U test). T cells could be identified crossing the basement membrane of tubules and invading renal tubules on transmission electron microscopy ( Figure 7C ). However, few GR1 þ neutrophils were identified in the allograft and B cell depletion had no effect on their presence ( Figure S3 To identify the mechanism of T cell recruitment, we isolated intra-allograft B cells from CAD kidneys at 4 weeks following transplantation. Ex vivo culture revealed B cells were activated to synthesize T cell chemokines, including GRO-a (CXCL1), RANTES (CCL5) and IP-10 (CXCL10) ( Figure 8A , p ¼ 0.0035, p ¼ 0.0005, p ¼ 0.0093, respectively; ANOVA). Generation of these chemokines was not dependent on re-stimulation and levels were significantly higher than produced by naive B cells stimulated by ionomycin and phorbitol myrisate acetate. Isolated intraallograft B cells also secreted multiple pro-inflammatory cytokines, including IL-6, IL-18, and TNF-a ( Figure 8A , p < 0.001, ANOVA). In addition IL-10 was assayed but was not detected in stimulated B cell supernatant (data not shown). To confirm the generation of these cytokines in vivo by B cells, intra-allograft B cells were sorted into pure CD45.2 þ B220 þ populations; mRNA was immediately isolated and analyzed for the most abundantly expressed cytokines ( Figure 8B) .
Reduced fibrosis is associated with lower monocyte and fibroblast density
Type III collagen was detected in this model of CAD ( Figure 9A ). Late B cell depletion reduced type III collagen expression in the allograft kidney at both 8 and 12 weeks ( Figure 9B , both p < 0.0001, U test), in keeping with reduced picrosirius red staining ( Figure 4A ). Intra-allograft F4/80 þ cells were reduced by late B cell depletion after transplantation ( Figure 9B Table S1 for absolute values; n ¼ 5, assay in duplicate, mean [SEM], ANOVA, and Bonferonni post hoc between groups; Ã p < 0.05; ÃÃ p < 0.01; ]p < 0.001 against all groups). (B) Flow cytometry of live splenocytes incubated with transplant recipient serum to detect donor-specific IgG, quantification by median fluorescent intensity (n ¼ 6, assay in triplicate, error bars median and interquartile-range, ANOVA, and Bonferonni post hoc between groups; ÃÃÃ p < 0.001). (C) Intra-allograft IgG content with representative immunofluorescence comparing na€ ıve kidney and of CAD allograft 12 weeks posttransplantation demonstrating deposited IgG (green) and B cells bearing IgG. Quantification of IgGþ micrographs following treatment (n ¼ 6, mean AE SEM, Mann-Whitney U test, N.S.). 12 weeks p < 0.0001, U test). Interestingly, there was no difference in a-SMA þ myofibroblasts between placebo and B cell depletion ( Figure 9B, 8 weeks p ¼ 0.25 and 12 weeks p ¼ 0.82, U test); a-SMA was restricted to intrarenal vessels and was not identified in proximity to type III collagen on serial sections ( Figure 9A) . Additionally, the level of transgelin ( Figure 9B, 12 weeks p < 0.0001, U test) and PDGFR-b expression ( Figure 9B, 8 weeks p ¼ 0.420 and 12 weeks p < 0.0001, U test) were significantly reduced in B cell depletion and followed the same pattern as type III collagen in the renal parenchyma ( Figure 9A ).
The supernatant of ex vivo cultured isolated intra-allograft B cells was analyzed to explore the role of activated B cells in fibrosis and significant levels of monocyte cytokines MCP-1 (CCL2), MCP-3 (CCL7), and MIP-2 (CXCL2) were found ( Figure 10A , p ¼ 0.0401, p ¼ 0.0334, p ¼ 0.0002, respectively; ANOVA). Furthermore, stimulation of B cells with irradiated C57BL/6 BM12 splenocytes stimulated the synthesis of TGF-b1, MIP-1a, and MIP-1b ( Figure 10A , p ¼ 0.0074, p ¼ 0.0232, p ¼ 0.0298, respectively; ANOVA); mRNA expression of the most abundant cytokines was confirmed in freshly isolated B cells ( Figure 10B ).
Discussion
In this study, we have demonstrated a key function of intraallograft B cells to be the secretion of cytokines. The depletion of intra-allograft B cells reduced T cell accumulation and fibroblastic cells that mediate interstitial fibrosis. In addition, intra-allograft B cells expressed the costimulatory molecule, CD86, as a marker of an antigen-presenting cell. CD86 expression by antigen presenting cells play an important role in costimulation for T cell activation (25) . Recent study of acute rejection in human renal transplant biopsies correlated the presence of CD20 þ B cell clusters with steroid resistant T cell-mediated cellular rejection (5); intriguingly, B cell clusters have also been identified in chronically rejected transplants (26, 27) , and in relation to lymphatic neoangiogenesis (28) , as such, much is still unknown about the role of intra-allograft B cells in transplantation. In this model, B cells appear as nodular infiltrates in a perivascular distribution, mimicking that described in human studies (3, 26) . These results are in agreement with previous studies using this donor and recipient combination, modeling rejection in both cardiac (29) , and renal transplantation (20) . Furthermore, the compartmentalization of intra-allograft B cells into TLT was suggested by the presence of B cells that expressed surface markers which had some similarities with those found in spleen (30) .
Type III collagen is a fibrillar protein that is synthesized in inflammation and present in chronic rejection of human renal allografts (31) , and was detected in this model. Despite the association between intra-allograft B cells and interstitial fibrosis, this was not mediated through a-SMAexpressing myofibroblasts, although the expression of a-SMA is associated with a great degree of variability (32, 33) . Other mechanisms promoting fibrosis were, therefore, examined: activated pericytes express platelet derived growth factor receptor-b (PDGFR-b) and can differentiate into fibroblasts (34) . Transgelin is an actin stress fiberassociated protein and an early marker of smooth muscle cell differentiation, and is associated with renal fibroblast activation (35) . Both transgelin and PDGFR-b, which may be alternative markers of fibroblast activation, were expressed in areas of tubular atrophy and we speculate that B cells could potentially drive fibrocyte or fibroblast activation through these mechanisms.
Increasingly, it is recognized that B cells may be an important source of pro-inflammatory and anti-inflammatory cytokines (18) . We found that intra-allograft B cells synthesize GRO-a, IL-6, RANTES, CXCL-10, and MCP-1 in the greatest abundance and that B cells can be further induced by restimulation with donor antigens. The most highly synthesized of these cytokines was GRO-a, which has been reported to be a major stimulus for neutrophil chemotaxis (36) ; however, there were very few neutrophils present in the allograft tissue, suggesting an alternative role for this cytokine. Recently, GRO-a has been shown to play a role in angiogenesis (37); therefore, it is hypothesized that GRO-a plays a role in TLT development as B cell depletion inhibited the formation of germinal centers, high endothelial venules, and lymphatic expansion. The presence of B cells at sites of inflammation has been associated with fibrosis.
Specifically following myocardial infarction B cells induced local macrophage recruitment through MCP-3 (CCL7) production (11) . Similarly we found B cells synthesize this cytokine within the allograft, but to a lesser degree than MCP-1 (CCL2).
An interesting feature of this model of CAD is the generation of IgG auto-antibodies that appear to be IgG1 or IgG3 isotypes. Following C57BL/6 BM12 cardiac transplantation in C57BL/6 recipients, IgG auto-antibodies have been observed (38) . The IgG1 isotype is not capable of fixing complement, and in a cardiac allograft model, this isotype was not capable of mediating rejection; however, IgG1 may stimulate endothelial cells to produce CXCL1 and CCL2 which are potent chemo-attractants to neutrophils and macrophages (39) . Potentially intra-allograft B cells promote fibrosis by recruiting monocytes into the allograft, thereby, supporting macrophage-mediated fibrosis or directly activate profibrotic cells through TGF-b1. Intriguingly in patients that develop chronic renal transplant rejection de novo auto-antibodies have been detected (40) . Serum IgM was attenuated in B cell depleted animals; however, no significant change in isotype switched Ig or IgG deposition in the allograft was found. It is possible that even if the antibodies were not complement fixing they may still play a role in CAD by promoting Fc-receptor mediated functions in cells such as macrophages.
B cell depletion was performed by monoclonal anti-CD20 antibody depletion, with the human counterpart that has been widely used in human disease and its safety profile proven. However, when used in depletion prior to renal transplantation, this was shown to significantly increase acute rejection (16) . Some evidence in human studies supports the hypothesis that B cell depletion in late allograft failure may be beneficial beyond targeting antibodymediated rejection. In small series and case studies, rituximab, in addition to other immunomodulatory therapies, has been administered to patients with late allograft failure with improvement or return of function without any change in circulating DSA levels (41) (42) (43) (44) . One might speculate that this protection is against intragraft B cell production of the cytokines as described in our model.
Another issue raised in this study is that depletion of B cells prior to transplantation had no effect on CAD whereas depletion at 4 weeks posttransplantation inhibited CAD. Paradoxically in patients with long-term tolerance, a B cell specific signature has been identified (45), however, this was in peripheral blood samples. The allograft B cells in this study did not produce interleukin-10, this argues against an anti-inflammatory role for them. TGF b was produced by allograft B cells and has been associated with tolerance (46); however, it also well characterized as a profibrotic cytokine (47) . Thus ''regulatory B cells'' are under investigation and this highlights the complex nature of B cell compartments and the challenge in determining their modes of action.
Here, we have shown that intra-allograft B cells are a major source of cytokines that may orchestrate T cell and monocyte recruitment and thus contribute to chronic damage and scarring in the renal allograft. These findings suggest that intra-allograft B cells per se and their cytokine and chemokine pathways represent potential novel therapeutic target for therapy in human renal transplantation.
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